OncoCyte (OCX) Revenue & Revenue Breakdown
OncoCyte Revenue Highlights
Latest Revenue (Y)
$1.50M
Latest Revenue (Q)
$115.00K
OncoCyte Revenue by Period
OncoCyte Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | $1.50M | 56.89% |
| 2022-12-31 | $958.00K | -87.60% |
| 2021-12-31 | $7.73M | 535.44% |
| 2020-12-31 | $1.22M | 100.00% |
| 2019-12-31 | - | 100.00% |
| 2018-12-31 | - | 100.00% |
| 2017-12-31 | - | 100.00% |
| 2016-12-31 | - | 100.00% |
| 2015-12-31 | - | 100.00% |
| 2014-12-31 | - | 100.00% |
| 2013-12-31 | - | - |
OncoCyte generated $1.50M in revenue during NA 2023, up 56.89% compared to the previous quarter, and up Infinity% compared to the same period a year ago.
OncoCyte Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-09-30 | $115.00K | 10.58% |
| 2024-06-30 | $104.00K | -40.91% |
| 2024-03-31 | $176.00K | -43.95% |
| 2023-12-31 | $314.00K | -26.81% |
| 2023-09-30 | $429.00K | -7.34% |
| 2023-06-30 | $463.00K | 55.89% |
| 2023-03-31 | $297.00K | -108.37% |
| 2022-12-31 | $-3.55M | -449.07% |
| 2022-09-30 | $1.02M | -50.80% |
| 2022-06-30 | $2.07M | 45.15% |
| 2022-03-31 | $1.42M | -60.32% |
| 2021-12-31 | $3.59M | 264.74% |
| 2021-09-30 | $984.00K | -51.53% |
| 2021-06-30 | $2.03M | 80.60% |
| 2021-03-31 | $1.12M | 123.46% |
| 2020-12-31 | $503.00K | -9.37% |
| 2020-09-30 | $555.00K | 288.11% |
| 2020-06-30 | $143.00K | 793.75% |
| 2020-03-31 | $16.00K | 100.00% |
| 2019-12-31 | - | 100.00% |
| 2019-09-30 | - | 100.00% |
| 2019-06-30 | - | 100.00% |
| 2019-03-31 | - | 100.00% |
| 2018-12-31 | - | 100.00% |
| 2018-09-30 | - | 100.00% |
| 2018-06-30 | - | 100.00% |
| 2018-03-31 | - | 100.00% |
| 2017-12-31 | - | 100.00% |
| 2017-09-30 | - | 100.00% |
| 2017-06-30 | - | 100.00% |
| 2017-03-31 | - | 100.00% |
| 2016-12-31 | - | 100.00% |
| 2016-09-30 | - | 100.00% |
| 2016-06-30 | - | 100.00% |
| 2016-03-31 | - | 100.00% |
| 2015-12-31 | - | 100.00% |
| 2015-09-30 | - | 100.00% |
| 2015-06-30 | - | 100.00% |
| 2015-03-31 | - | 100.00% |
| 2014-12-31 | - | - |
OncoCyte generated $115.00K in revenue during Q3 2024, up 10.58% compared to the previous quarter, and up 24.84% compared to the same period a year ago.
OncoCyte Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| FONR | FONAR | $102.88B | $25.94M |
| SHC | Sotera Health Company | $1.05B | $285.47M |
| GTH | Genetron | $650.71M | $201.32M |
| BNR | Burning Rock Biotech | $537.43M | $125.62M |
| CSTL | Castle Biosciences | $219.79M | $85.78M |
| OLK | Olink AB (publ) | $169.91M | $28.59M |
| PSNL | Personalis | $73.48M | $22.58M |
| STIM | Neuronetics | $71.35M | $16.45M |
| TRIB | Trinity Biotech | $56.83M | $14.70M |
| XGN | Exagen | $52.55M | $15.06M |
| BDSX | Biodesix | $49.09M | $18.15M |
| PRPH | ProPhase Labs | $45.24M | $3.15M |
| DRIO | DarioHealth | $20.35M | $6.25M |
| PRPO | Precipio | $12.40M | $4.44M |
| ISPC | iSpecimen | $9.93M | $2.86M |
| INBS | Intelligent Bio Solutions | $3.11M | $872.29K |
| OCX | OncoCyte | $1.50M | $115.00K |
| SERA | Sera Prognostics | $306.00K | $24.00K |